P. Laurent-Puig

CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification

P. Laurent-Puig, A. Reyniès, A. de Reyniès, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study.

P. Laurent-Puig, J. Galon, A. Duval, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapy

P. Laurent-Puig, H. Lenz, W. Zhang, 2013, The Pharmacogenomics Journal.

Standardizing data collection in adjuvant colon cancer trials: A consensus project from the IDEA and ACCENT international consortia and national experts.

J. Meyerhardt, A. Sobrero, J. Souglakos, 2024, European journal of cancer.

Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy

P. Laurent-Puig, D. Vernerey, J. Taieb, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular classification of pulmonary sarcomatoid carcinomas suggests new therapeutic opportunities

P. Laurent-Puig, H. Blons, M. Antoine, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers

P. Laurent-Puig, J. Salleron, J. Merlin, 2015, British Journal of Cancer.

Breast cancer, early stage

M. Espié, C. Mermel, R. Gelber, 2012 .